Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04611126
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:27.297603+00:00
Published At
2025-08-12T00:00:00+00:00
Record Updated At
2025-08-12
Results Posted At
2025-08-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Ovarian Cancer", "Metastatic Fallopian Tube Cancer", "Peritoneal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-08-12"
protocolSection.identificationModule.nctId
"NCT04611126"
protocolSection.identificationModule.officialTitle
"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-08-12"

Study condition terms

  • Metastatic Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Peritoneal Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.